Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Famciclovir - Novartis

Next Previous
X
Search
Drug Profile

Famciclovir - Novartis

Alternative Names: AK-120; BRL-42810; Famvir

Latest Information Update: 08 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Asahi Kasei Pharma Corp; Astellas Pharma; GSK; Maruho; Novartis; Solvay
  • Class Antivirals; Nucleosides; Purines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Herpes simplex virus infections; Herpes zoster; Herpesvirus infections
  • No development reported Herpes labialis
  • Discontinued Epstein-Barr virus infections; Hepatitis B

Most Recent Events

  • 21 Feb 2019 Registered for Herpes simplex virus infections (Recurrent) in Japan (PO)
  • 01 Dec 2018 Preregistration for Herpes simplex virus infections (Recurrent) in Japan (PO) before February 2019
  • 31 Oct 2018 Maruho completes a phase III trial for Herpes simplex virus infections (Recurrent) in Japan (PO) (JapicCTI-163223)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top